Ahead of a biotech forum in San Francisco today, Forbes contributor Nathan Sadeghi-Nejad...

|By:, SA News Editor

Ahead of a biotech forum in San Francisco today, Forbes contributor Nathan Sadeghi-Nejad examines the progress of cancer stem cells (CSC) in fighting tumors. Bulls think CSC therapies will "dramatically improve patient outcomes," while bears say that the data is "inconclusive or that expectations are unreasonably high." Sadeghi-Nejad is "somewhere in the middle." One listed player is Verastem (VSTM).